Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer

References

• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022 Jan;72(1):7–33.
   PubMed Web of Science ®Google Scholar
• Desai MM, Cacciamani GE, Gill K, et al. Trends in incidence of metastatic prostate cancer in the US. JAMA Network Open. 2022 Mar 1;5(3):e222246.
   PubMed Web of Science ®Google Scholar
• de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020 May 28;382(22):2091–2102.
   PubMed Web of Science ®Google Scholar
• de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010 Oct 2;376(9747):1147–1154.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010 Jul 29;363(5):411–422.
   PubMed Web of Science ®Google Scholar
• Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013 Jul 18;369(3):213–223.
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012 Sep 27;367(13):1187–1197.
   PubMed Web of Science ®Google Scholar
• Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996 Jun;14(6):1756–1764.
   PubMed Web of Science ®Google Scholar
• Haberkorn U, Eder M, Kopka K, et al. New strategies in prostate cancer: Prostate-Specific Membrane Antigen (PSMA) ligands for diagnosis and therapy. Clin Cancer Res. 2016 Jan 1;22(1):9–15.
   PubMed Web of Science ®Google Scholar
• Kelkar SS, Reineke TM. Theranostics: combining imaging and therapy. Bioconjug Chem. 2011 Oct 19;22(10):1879–1903.
   PubMed Web of Science ®Google Scholar
• Lutetium Lu 177 vipivotide tetraxetan.: advanced accelerator applications USA, Inc; [July 15, 2022]. Available from: https://www.novartis.us/sites/www.novartis.us/files/pluvicto.pdf
   Google Scholar
• NCCN guidelines version 4.2022 prostate cancer. [July 15, 2022]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
   Google Scholar
• Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015 Aug 20;373(8):737–746.
   PubMed Web of Science ®Google Scholar
• Smith MR, Hussain M, Saad F, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022 Mar 24;386(12):1132–1142.
   PubMed Web of Science ®Google Scholar
• James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016 Mar 19;387(10024):1163–1177.
   PubMed Web of Science ®Google Scholar
• Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013 Feb;14(2):149–158.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Foulon S, Carles J, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design. Lancet. 2022 Apr 30;399(10336):1695–1707.
   PubMed Web of Science ®Google Scholar
• van Soest RJ, Efstathiou JA, Sternberg CN, et al. The natural history and outcome predictors of metastatic castration-resistant prostate cancer. Eur Urol Focus. 2016 Dec;2(5):480–487.
   PubMedGoogle Scholar
• Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015 Feb;16(2):152–160.
   PubMed Web of Science ®Google Scholar
• de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011 May 26;364(21):1995–2005.
   PubMed Web of Science ®Google Scholar
• Loriot Y, Bianchini D, Ileana E, et al. Antitumour activity of Abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol. 2013 Jul;24(7):1807–1812.
   PubMed Web of Science ®Google Scholar
• Bianchini D, Lorente D, Rodriguez-Vida A, et al. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and Abiraterone. Eur J Cancer. 2014 Jan;50(1):78–84.
   PubMed Web of Science ®Google Scholar
• Schrader AJ, Boegemann M, Ohlmann CH, et al. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and Abiraterone. Eur Urol. 2014 Jan;65(1):30–36.
   PubMed Web of Science ®Google Scholar
• Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018 Apr 12;378(15):1408–1418.
   PubMed Web of Science ®Google Scholar
• Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014 Jul 31;371(5):424–433.
   PubMed Web of Science ®Google Scholar
• Khalaf DJ, Annala M, Taavitsainen S, et al. Optimal sequencing of enzalutamide and Abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncol. 2019 Dec;20(12):1730–1739.
   PubMed Web of Science ®Google Scholar
• Noonan KL, North S, Bitting RL, et al. Clinical activity of Abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol. 2013 Jul;24(7):1802–1807.
   PubMed Web of Science ®Google Scholar
• Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008 Jan 10;26(2):242–245.
   PubMed Web of Science ®Google Scholar
• Berry W, Dakhil S, Modiano M, et al. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol. 2002 Dec;168(6):2439–2443.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999 Aug;17(8):2506–2513.
   PubMed Web of Science ®Google Scholar
• Nilsson S, Cislo P, Sartor O, et al. Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Ann Oncol. 2016 May;27(5):868–874.
   PubMed Web of Science ®Google Scholar
• Al-Ezzi EM, Alqaisi HA, Iafolla MAJ, et al. Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223. Cancer Med. 2021 Sep;10(17):5775–5782.
   PubMed Web of Science ®Google Scholar
• Abida W, Campbell D, Patnaik A, et al. Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 study. Clin Cancer Res. 2020 Jun 1;26(11):2487–2496.
   PubMed Web of Science ®Google Scholar
• Hussain M, Mateo J, Fizazi K, et al. Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med. 2020 Dec 10;383(24):2345–2357.
   PubMed Web of Science ®Google Scholar
• Banerjee S, Pillai MR, Knapp FF. Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry, and practical applications. Chem Rev. 2015 Apr 22;115(8):2934–2974.
   PubMed Web of Science ®Google Scholar
• Caromile LA, Dortche K, Rahman MM, et al. PSMA redirects cell survival signaling from the MAPK to the PI3K-AKT pathways to promote the progression of prostate cancer. Sci Signal. 2017 Mar 14;10(470). DOI:10.1126/scisignal.aag3326.
   PubMed Web of Science ®Google Scholar
• Benesova M, Schafer M, Bauder-Wust U, et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2015 Jun;56(6):914–920.
   PubMed Web of Science ®Google Scholar
• Ruigrok EAM, van Vliet N, Dalm SU, et al. Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy. Eur J Nucl Med Mol Imaging. 2021 May;48(5):1339–1350.
   PubMed Web of Science ®Google Scholar
• Herrmann K, Rahbar K, Eiber M, et al. Dosimetry of 177 Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: results from the VISION trial sub-study. J Clin Oncol. 2022;40(6_suppl):97. .
   Google Scholar
• Kratochwil C, Giesel FL, Stefanova M, et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-Labeled PSMA-617. J Nucl Med. 2016 Aug;57(8):1170–1176.
   PubMed Web of Science ®Google Scholar
• Schuchardt C, Zhang J, Kulkarni HR, et al. Prostate-specific membrane antigen radioligand therapy using (177)Lu-PSMA I&T and (177)Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution and dosimetry. J Nucl Med. 2022 Aug;63(8):1199–1207.
   Google Scholar
• Fendler WP, Kratochwil C, Ahmadzadehfar H, et al. 177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer. Nuklearmedizin. 2016 Jun 28;55(3):123–128.
   PubMedGoogle Scholar
• Kamaldeep WG, Sahu SK, Sahu SK, et al. Examining absorbed doses of indigenously developed 177 Lu-PSMA-617 in metastatic castration-resistant prostate cancer patients at baseline and during course of peptide receptor radioligand therapy. Cancer Biother Radiopharm. 2021 Apr;36(3):292–304.
   PubMed Web of Science ®Google Scholar
• Rathke H, Giesel FL, Flechsig P, et al. Repeated (177)Lu-labeled PSMA-617 radioligand therapy using treatment activities of Up to 9.3 GBq. J Nucl Med. 2018 Mar;59(3):459–465.
   PubMed Web of Science ®Google Scholar
• Violet J, Jackson P, Ferdinandus J, et al. Dosimetry of (177)Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes. J Nucl Med. 2019 Apr;60(4):517–523.
   PubMed Web of Science ®Google Scholar
• Calais J, Gafita A, Eiber M, et al. Prospective phase 2 trial of PSMA-targeted molecular radiotherapy with (177)Lu-PSMA-617 for metastatic castration-reSISTant prostate cancer (RESIST-PC): efficacy results of the UCLA cohort. J Nucl Med. 2021 Oct;62(10):1440–1446.
   PubMed Web of Science ®Google Scholar
• Afshar-Oromieh A, Hetzheim H, Kratochwil C, et al. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med. 2015 Nov;56(11):1697–1705.
   PubMed Web of Science ®Google Scholar
• Delker A, Fendler WP, Kratochwil C, et al. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):42–51.
   PubMed Web of Science ®Google Scholar
• Hohberg M, Eschner W, Schmidt M, et al. Lacrimal glands may represent organs at risk for radionuclide therapy of prostate cancer with [(177)Lu]DKFZ-PSMA-617. Mol Imaging Biol. 2016 Jun;18(3):437–445.
   PubMed Web of Science ®Google Scholar
• Kabasakal L, AbuQbeitah M, Aygun A, et al. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):1976–1983.
   PubMed Web of Science ®Google Scholar
• Kratochwil C, Giesel FL, Eder M, et al. [(1)(7)(7)Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2015 May;42(6):987–988.
   PubMed Web of Science ®Google Scholar
• Ahmadzadehfar H, Rahbar K, Kurpig S, et al. Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res. 2015 Dec;5(1):114.
   PubMedGoogle Scholar
• Rahbar K, Bode A, Weckesser M, et al. Radioligand therapy with 177Lu-PSMA-617 as A novel therapeutic option in patients with metastatic castration resistant prostate cancer. Clin Nucl Med. 2016 Jul;41(7):522–528.
   PubMed Web of Science ®Google Scholar
• Rahbar K, Schmidt M, Heinzel A, et al. Response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis. J Nucl Med. 2016 Sep;57(9):1334–1338.
   PubMed Web of Science ®Google Scholar
• Rahbar K, Ahmadzadehfar H, Kratochwil C, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017 Jan;58(1):85–90.
   PubMed Web of Science ®Google Scholar
• Hope TA. From compassionate use to phase 3 trial: the impact of Germany’s PSMA-617 Literature. J Nucl Med. 2020 Dec;61(Suppl 2):255S–256S.
   PubMedGoogle Scholar
• Hofman MS, Violet J, Hicks RJ, et al. [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018 Jun;19(6):825–833.
   PubMed Web of Science ®Google Scholar
• Emmett L, Crumbaker M, Ho B, et al. Results of a prospective phase 2 pilot trial of (177)Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer including imaging predictors of treatment response and patterns of progression. Clin Genitourin Cancer. 2019 Feb;17(1):15–22.
   PubMed Web of Science ®Google Scholar
• Hofman MS, Emmett L, Sandhu S, et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021 Feb 27;397(10276):797–804.
   PubMed Web of Science ®Google Scholar
• Hofman MS EL, Sandhu S, Minnema MC, et al. TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel—overall survival after median follow-up of 3 years (ANZUP 1603). J Clin Oncol. 2022;40(1):40. .
   PubMedGoogle Scholar
• Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021 Sep 16;385(12):1091–1103.
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Castellano D, de Bono J, et al. Efficacy and safety of cabazitaxel versus abiraterone or enzalutamide in older patients with metastatic castration-resistant prostate cancer in the CARD study. Eur Urol. 2021 Oct;80(4):497–506.
   PubMed Web of Science ®Google Scholar
• Baumgarten J, Groener D, Nguyen Ngoc C, et al. Safety and efficacy of (177)Lutetium-PSMA-617 radioligand therapy shortly after failing (223)radium-dichloride. Cancers (Basel). 2022 Jan 22;14(3):557.
   PubMed Web of Science ®Google Scholar
• Groener D, Nguyen CT, Baumgarten J, et al. Hematologic safety of (177)Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer. EJNMMI Res. 2021 Jul 3;11(1):61.
   PubMed Web of Science ®Google Scholar
• Crumbaker M, Pathmanandavel S, Yam AO, et al. Phase I/II trial of the combination of (177)lutetium prostate specific membrane antigen 617 and Idronoxil (NOX66) in men with end-stage metastatic castration-resistant prostate cancer (LuPIN). Eur Urol Oncol. 2021 Dec;4(6):963–970.
   PubMed Web of Science ®Google Scholar
• Prive BM, Peters SMB, Muselaers CHJ, et al. Lutetium-177-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer: a prospective pilot study. Clin Cancer Res. 2021 Jul 1;27(13):3595–3601.
   PubMed Web of Science ®Google Scholar
• United States Regulatory Commission. 35.2 Definitions. [updated January 16, 2019]. Available from: https://www.nrc.gov/reading-rm/doc-collections/cfr/part035/part035-0002.html
   Google Scholar
• Hotta M, Gafita A, Murthy V, et al. Predicting the outcome of mCPRC patients after Lu-177 PSMA therapy using semi-quantitative and visual criteria in baseline PSMA PET: an international multicenter retrospective study. J Clin Oncol. 2022;40(6_suppl):32–32.
   PubMed Web of Science ®Google Scholar
• Dietlein M, Kobe C, Kuhnert G, et al. Comparison of [(18)F]DCFPyL and [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging Biol. 2015 Aug;17(4):575–584.
   PubMed Web of Science ®Google Scholar
• De Man K, Van Laeken N, Schelfhout V, et al. (18)F-PSMA-11 Versus (68)Ga-PSMA-11 positron emission tomography/computed tomography for staging and biochemical recurrence of prostate cancer: a prospective double-blind randomised cross-over trial. Eur Urol. 2022 Jun 8;82(5):501–509.
   PubMedGoogle Scholar
• Seifert R, Kessel K, Schlack K, et al. PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [(177)Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis. Eur J Nucl Med Mol Imaging. 2021 Apr;48(4):1200–1210.
   PubMed Web of Science ®Google Scholar
• Kuo P, Hesterman J, Rahbar K, et al. [68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: a VISION substudy. J Clin Oncol. 2022;40(16_suppl):5002–5002.
   Google Scholar
• Buteau JP, Martin AJ, Emmett L, et al. PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603). J Clin Oncol. 2022;40(6_suppl):10–10.
   Web of Science ®Google Scholar
• Michalski K, Ruf J, Goetz C, et al. Prognostic implications of dual tracer PET/CT: PSMA ligand and [(18)F]FDG PET/CT in patients undergoing [(177)Lu]PSMA radioligand therapy. Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):2024–2030.
   PubMed Web of Science ®Google Scholar
• Hartrampf PE, Lapa C, Serfling SE, et al. Development of discordant hypermetabolic prostate cancer lesions in the course of [(177)Lu]PSMA radioligand therapy and their possible influence on patient outcome. Cancers (Basel). 2021 Aug 25;13(17):4270.
   PubMed Web of Science ®Google Scholar
• Violet J, Sandhu S, Iravani A, et al. Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of (177)Lu-PSMA-617 theranostics in metastatic castration-resistant prostate cancer. J Nucl Med. 2020 Jun;61(6):857–865.
   PubMed Web of Science ®Google Scholar
• Yordanova A, Linden P, Hauser S, et al. Outcome and safety of rechallenge [(177)Lu]Lu-PSMA-617 in patients with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2019 May;46(5):1073–1080.
   PubMed Web of Science ®Google Scholar
• Feuerecker B, Tauber R, Knorr K, et al. Activity and adverse events of actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of lutetium-177-PSMA. Eur Urol. 2021 Mar;79(3):343–350.
   PubMed Web of Science ®Google Scholar
• Emmett L, Yin C, Crumbaker M, et al. Rapid modulation of PSMA expression by androgen deprivation: serial (68)Ga-PSMA-11 PET in Men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade. J Nucl Med. 2019 Jul;60(7):950–954.
   PubMed Web of Science ®Google Scholar
• Hope TA, Truillet C, Ehman EC, et al. 68Ga-PSMA-11 PET imaging of response to androgen receptor inhibition: first human experience. J Nucl Med. 2017 Jan;58(1):81–84.
   PubMed Web of Science ®Google Scholar
• Harsini S, Saprunoff H, Alden T, et al. The effects of monosodium glutamate on PSMA radiotracer uptake in men with recurrent prostate cancer: a prospective, randomized, double-blind, placebo-controlled intraindividual imaging study. J Nucl Med. 2021 Jan;62(1):81–87.
   PubMed Web of Science ®Google Scholar
• Langbein T, Chausse G, Baum RP. Salivary gland toxicity of PSMA radioligand therapy: relevance and preventive strategies. J Nucl Med. 2018 Aug;59(8):1172–1173.
   PubMed Web of Science ®Google Scholar
• Mohan V, Bruin NM, van de Kamer JB, et al. The effect of eating on the uptake of PSMA ligands in the salivary glands. EJNMMI Res. 2021 Sep 26;11(1):95.
   PubMed Web of Science ®Google Scholar
• Rathke H, Kratochwil C, Hohenberger R, et al. Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing (225)Ac-PSMA-617 RLT. Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):139–147.
   PubMed Web of Science ®Google Scholar
• Rosar F, Kochems N, Bartholoma M, et al. Renal safety of [177Lu]Lu-PSMA-617 radioligand therapy in patients with compromised baseline kidney Function. Cancers (Basel). 2021 Jun 21;13(12):3095.
   PubMed Web of Science ®Google Scholar
• Strosberg JR, Caplin ME, Kunz PL, et al. (177)Lu-Dotatate plus long-acting octreotide versus high dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021 Dec;22(12):1752–1763.
   PubMed Web of Science ®Google Scholar
• Song H, Guja KE, Iagaru A. PSMA theragnostics for metastatic castration resistant prostate cancer. Transl Oncol. 2022 Aug;22:101438.
   PubMed Web of Science ®Google Scholar